Alphatec Holdings, Inc. achieved a total revenue of $177 million in Q4 2024, demonstrating strong growth in surgical revenue by 28%. The company also reported a GAAP net loss of $33 million and generated $9 million in free cash flow, positioning itself for self-funded growth in the coming years.
Total revenue for Q4 2024 reached $177 million.
Surgical revenue grew by 28% in Q4 2024, driven by 19% surgical volume growth and a 7% increase in average revenue per surgery.
The company increased new surgeon users by 20% during the quarter.
Alphatec successfully entered the Japan market with its first surgery and generated $9 million of free cash flow in Q4 2024.
For the full year 2025, Alphatec Holdings, Inc. expects total revenue to approximate $732 million, representing approximately 20% growth compared to full year 2024. This includes surgical revenue of approximately $657 million and EOS revenue of approximately $75 million. The company also anticipates adjusted EBITDA of approximately $75 million, contributing to positive free cash flow.
Analyze how earnings announcements historically affect stock price performance